BS_52MPKTJH
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 9.494086727989487
- age_years
- 13.178
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.335
- SPERMATOGENESIS+0.186
- PANCREAS_BETA_CELLS+0.142
- MYOGENESIS+0.110
- APICAL_JUNCTION-0.055
- HEDGEHOG_SIGNALING-0.062
- ESTROGEN_RESPONSE_EARLY-0.094
- ESTROGEN_RESPONSE_LATE-0.104
- HEME_METABOLISM-0.111
- MITOTIC_SPINDLE-0.125
Top 10 suppressed
- MYC_TARGETS_V1-0.613
- INTERFERON_ALPHA_RESPONSE-0.588
- TGF_BETA_SIGNALING-0.493
- INTERFERON_GAMMA_RESPONSE-0.476
- PROTEIN_SECRETION-0.471
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- MYC_TARGETS_V2-0.457
- E2F_TARGETS-0.434
- MTORC1_SIGNALING-0.432
- OXIDATIVE_PHOSPHORYLATION-0.431
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_90B22NGP | ATRT | — | 0.981 |
| 2 | SRR602927 | GTEX | — | 0.958 |
| 3 | BS_J71N7D09 | medulloblastoma | — | 0.955 |
| 4 | MNG700 | — | — | 0.952 |
| 5 | BS_FEPRNEXX | Embryonal tumors | — | 0.950 |
| 6 | SRR4195666 | — | — | 0.950 |
| 7 | BS_3P20Q2C3 | low-grade glioma | — | 0.949 |
| 8 | BS_2XD3MNKD | Glial-neuronal tumor NOS | — | 0.949 |
| 9 | BS_0Y66ZBWE | low-grade glioma | — | 0.947 |
| 10 | SRR627425 | GTEX | — | 0.944 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.335 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.186 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.142 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |